This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of other and ill-defined sites
C3_OTHER_OR_ILLDEFINED_SITES
benign neoplasm: A neoplasm which is characterized by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumor cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and do not metastasize to other anatomic sites.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
116 |
4. Check minimum number of eventsNone |
116 |
5. Include endpointsNone |
116 |
6. Filter based on genotype QC (FinnGen only) |
114 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and ill-defined sites
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other and ill-defined sites, including Hilmo
- Secondary uncertain malignant neoplasm
- Solid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 114 | 37 | 77 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.04 |
| Median age at first event (years) | 74.08 | 78.41 | 72.00 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 116
- Matched controls
- 1160
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
+∞
55.8
49
*
130
Kela drug reimbursment
Malignant tumour
+∞
35.2
32
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.1
22.0
36
61
8000/3-C76.2
ICD-O-3
Neoplasm, malignant of abdomen, NOS
+∞
19.3
18
*
H02AB02
ATC
dexamethasone; systemic
42.1
14.9
18
5
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
13.8
13
*
Z51.5
ICD-10 Finland
Palliative care
12.8
13.5
24
23
8140/3-C76.2
ICD-O-3
Adenocarcinoma, NOS, of abdomen, NOS
+∞
11.6
11
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
10.6
10
*
8000/3-C80.9
ICD-O-3
Neoplasm, malignant of unknown primary site
+∞
10.6
10
*
C76.0
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Head, face and neck
+∞
9.5
9
*
C76.1
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Thorax
+∞
9.5
9
*
C76.3
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Pelvis
+∞
8.4
8
*
C80
ICD-10 Finland
Malignant neoplasm, without specification of site
+∞
8.4
8
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
11.2
7.8
14
14
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
8140/3-C80.9
ICD-O-3
Adenocarcinoma, NOS, of unknown primary site
+∞
7.4
7
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
7.4
7
*
R18
ICD-10 Finland
Ascites
32.2
7.3
9
*
N02AA05
ATC
oxycodone; systemic
3.3
7.0
32
120
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
+∞
6.3
6
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
+∞
6.3
6
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
6.3
6
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
6.3
6
*
JN4BD
NOMESCO Finland
Extensive body CT
6.0
6.1
16
30
H25.1
ICD-10 Finland
Senile nuclear cataract
0.3
6.1
14
407
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
6
0
+∞
6.30
1.0
0.0
25.94
—
ug/l
—
6
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
20
7.17
5.74
1.9
2.3
0.23
0.31
u/ml
—
8
9
8
17
4.97
2.97
1.3
1.2
—
—
—
0
0
36
534
0.53
2.57
32.6
19.1
14.57
15.15
%
1.14
36
514
44
606
0.56
2.35
6.6
6.8
43.33
42.66
mmol/mol
0.15
38
541
21
109
2.13
2.28
1.6
1.8
0.77
0.83
mmol/l
1.44
21
96
53
682
0.59
2.06
32.3
18.6
94.02
88.47
umol/l
0.38
53
682
25
145
1.92
2.02
3.1
1.9
—
—
—
0
0
49
636
0.60
1.90
5.0
5.0
6.19
6.23
mmol/l
0.08
42
540
5
12
4.30
1.84
1.2
1.5
297.60
101.18
u/ml
—
5
12
5
12
4.30
1.84
1.2
2.4
85.60
81.50
%
—
5
12
47
606
0.62
1.68
4.1
4.7
4.38
4.27
mmol/l
0.34
41
531
50
633
0.63
1.63
4.4
5.2
2.51
2.44
mmol/l
0.25
42
547
5
17
3.02
1.37
1.0
1.4
—
—
—
0
0
13
222
0.53
1.32
5.4
3.6
23.30
26.64
%
—
7
107
48
597
0.67
1.32
4.2
4.7
1.42
1.40
mmol/l
0.09
41
515
46
575
0.67
1.28
3.9
4.3
1.22
1.27
mmol/l
0.24
38
488
8
38
2.19
1.21
7.9
7.0
23.31
24.58
mmol/l
—
8
38
10
50
2.09
1.20
1.6
1.6
—
—
—
0
0
10
52
2.01
1.10
1.3
1.8
—
—
—
0
0
20
288
0.63
1.06
5.5
3.9
2.30
2.40
ug/l
0.05
20
249
44
347
1.43
1.03
8.6
3.5
17.67
12.89
umol/l
0.71
44
321
24
168
1.54
1.00
2.2
2.4
364.35
9090.11
umol/l
1.32
17
138
45
359
1.41
0.98
7.4
4.6
1.21
1.21
mmol/l
0.22
40
288
50
591
0.73
0.89
5.0
4.5
2.08
2.11
mu/l
0.05
45
496
35
274
1.40
0.84
3.3
2.2
—
—
—
0
0
43
349
1.37
0.83
8.6
5.3
4.82
4.78
e9/l
0.03
33
298
6
32
1.92
0.83
1.2
1.3
—
—
—
0
0
15
99
1.59
0.80
4.0
3.5
1.17
1.02
mmol/l
0.72
15
84
0
26
0.00
0.79
0.0
2.1
—
—
—
0
0
26
331
0.72
0.71
7.0
5.4
0.00
0.00
estimate
—
6
52
14
196
0.68
0.64
4.2
4.5
0.00
0.00
estimate
—
6
53
21
270
0.73
0.60
5.3
4.5
—
—
—
0
0
27
332
0.76
0.58
4.3
4.2
0.00
0.00
estimate
—
6
52
6
36
1.70
0.57
3.0
2.6
1.42
1.06
%
—
6
36
24
300
0.75
0.57
1.7
2.5
—
—
—
0
0
27
329
0.77
0.54
4.7
4.2
0.00
0.00
estimate
—
7
60
6
40
1.53
0.52
11.7
7.7
1.07
1.37
%
—
6
40
6
40
1.53
0.52
11.7
7.7
0.65
0.73
%
—
6
40
15
110
1.42
0.52
3.9
2.4
1.46
1.30
e6/l
—
5
63
15
111
1.40
0.49
3.9
2.7
2.98
2.68
e6/l
—
5
63
8
58
1.41
0.42
1.8
1.6
—
—
—
0
0
5
35
1.45
0.40
1.4
1.3
—
—
—
0
0
44
396
1.18
0.32
19.0
19.3
1.42
1.41
inr
0.01
11
127
43
475
0.85
0.32
4.0
3.5
15.06
15.22
pmol/l
0.15
38
406
24
204
1.22
0.32
3.7
2.7
0.59
0.58
e6/l
0.02
17
158
29
255
1.18
0.28
4.2
3.0
—
—
—
0
0
35
314
1.16
0.26
6.5
3.1
30.73
34.51
g/l
2.22
35
282
26
228
1.18
0.25
1.9
2.1
3.18
3.01
mg/l
0.15
21
185
17
143
1.22
0.25
1.5
1.7
—
—
—
0
0
12
97
1.26
0.24
1.3
1.7
—
—
—
0
0
5
37
1.37
0.24
1.6
1.4
—
—
—
0
0
5
40
1.26
0.22
1.6
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
12
100
1.22
0.19
1.3
1.6
—
—
—
0
0
11
91
1.23
0.18
9.9
4.9
102.73
104.49
mmol/l
0.47
11
91
32
344
0.90
0.14
2.2
2.2
107.23
87.19
pmol/l
0.79
20
179
19
208
0.90
0.11
2.3
1.9
1441.22
1215.67
nmol/l
0.28
13
148
10
86
1.18
0.11
9.1
5.1
11.70
10.54
kpa
—
10
81
10
86
1.18
0.11
9.1
5.1
0.37
1.61
mmol/l
—
10
64
10
86
1.18
0.11
9.1
5.1
5.24
5.01
kpa
—
10
81
26
276
0.93
0.08
2.2
2.2
70.61
79.08
nmol/l
0.79
21
230
10
90
1.12
0.05
3.8
3.8
—
—
—
0
0
37
373
0.99
0.00
3.5
2.8
138.00
51.15
u/l
1.26
32
333
24
241
0.99
0.00
4.0
3.3
19.38
6.65
mg/mmol
0.47
16
160
5
55
0.91
0.00
4.6
2.7
84.00
87.77
ng/l
—
5
48
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
8
87
0.91
0.00
4.0
9.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
0.78
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_OTHER_OR_ILLDEFINED_SITES – Malignant neoplasm of other and ill-defined sites
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).